Assignee
STINGRAY THERAPEUTICS INC
US·5 granted patents·3 pending applications·5 citations·filing 2018–2024
Top patents by PatentIndex Score
8 records- 0187US11591313B2Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereofSTINGRAY THERAPEUTICS INC·Filed 2021·Granted Feb 28, 2023·2 cites·45 claims
- 0285US11407729B2Quinoline and quinazoline compounds and methods of use thereofSTINGRAY THERAPEUTICS INC·Filed 2020·Granted Aug 9, 2022·2 cites·3 claims
- 0376US2025092018A1Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereofSTINGRAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0472US12152015B2Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereofSTINGRAY THERAPEUTICS INC·Filed 2023·Granted Nov 26, 2024·0 cites·32 claims
- 0569US10689376B2Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeuticsSTINGRAY THERAPEUTICS INC·Filed 2018·Granted Jun 23, 2020·1 cites·4 claims
- 0662US11142524B2Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeuticsSTINGRAY THERAPEUTICS INC·Filed 2019·Granted Oct 12, 2021·0 cites·2 claims
- 0755US2025099493A1Phosphonates as inhibitors of enpp1 and cdnpSTINGRAY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0853US2024034727A1Imidazole compounds as inhibitors of enpp1STINGRAY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →